3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Terminated
2
Recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Breast Neoplasms
723
Neoplasms
461
Prostatic Neoplasms
398
Carcinoma, Non-Small-Cell Lung
388
Lung Neoplasms
311
Leukemia, Myeloid, Acute
301
Multiple Myeloma
270
Colorectal Neoplasms
243
Neoplasm Metastasis
240
Pancreatic Neoplasms
238
Leukemia
235
Melanoma
217
Lymphoma
213
Precursor Cell Lymphoblastic Leukemia-Lymphoma
204
Brain Neoplasms
195
Recurrence
178
Head and Neck Neoplasms
177
Lymphoma, Non-Hodgkin
174
Myelodysplastic Syndromes
168
Leukemia, Lymphocytic, Chronic, B-Cell
168
Ovarian Neoplasms
160
Carcinoma, Hepatocellular
154
Glioblastoma
149
Carcinoma, Renal Cell
137
Rectal Neoplasms
134
Colonic Neoplasms
129
Lymphoma, Large B-Cell, Diffuse
125
Lymphoma, Follicular
125
Hodgkin Disease
116
Squamous Cell Carcinoma of Head and Neck
109
Interventions
SLC-0111
1
IFL protocol
1
Gemcitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
OTHER
×
Metastatic Pancreatic Ductal Adenocarcinoma
×
Clear all
NCT03450018
2024-05-24
SLC-0111-17-01
British Columbia Cancer Agency
Phase 1/2
Terminated
6 enrolled
NCT03331640
2022-01-11
PANTHEON
AIO-Studien-gGmbH
Phase 2
Terminated
67 enrolled